Trial Profile
A Phase 1/2 Study Evaluating the Safety and Efficacy of IOV-2001 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 09 Mar 2023
Price :
$35
*
At a glance
- Drugs IOV 2001 (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2; Interleukin-2
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Iovance Biotherapeutics
- 06 Mar 2023 Planned End Date changed from 1 Jan 2023 to 1 Jul 2024.
- 06 Mar 2023 Planned primary completion date changed from 1 Oct 2022 to 1 Apr 2024.
- 14 Dec 2021 Study design has been released at the 63rd American Society of Hematology Annual Meeting and Exposition